Edwards Lifesciences Corp (EW.N)
73.40USD
1 Aug 2013
$2.02 (+2.83%)
$71.38
$72.42
$73.72
$72.31
223,569
256,301
$110.79
$62.35
About
Overall
| Beta: | 0.49 |
| Market Cap (Mil.): | $8,291.39 |
| Shares Outstanding (Mil.): | 112.96 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| EW.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 21.49 | 67.23 | 37.87 |
| EPS (TTM): | 3.42 | -- | -- |
| ROI: | 20.93 | 5.02 | 18.70 |
| ROE: | 26.49 | 9.82 | 19.53 |
Edwards Lifesciences beats estimates but outlook cautious
- Edwards Lifesciences Corp on Thursday reported a stronger-than-expected second-quarter profit on solid sales of its replacement heart valves, and its shares rose in after-hours trading.
UPDATE 3-Edwards Lifesciences beats estimates but outlook cautious
* U.S. 2nd-quarter sales of Sapien heart valves at $90 mln
Edwards Lifesciences earnings top expectations
- Edwards Lifesciences Corp on Thursday reported better-than-expected second-quarter earnings on solid sales of its replacement heart valves implanted in a less-invasive procedure than open-heart surgery.
Edwards Lifesciences quarterly earnings rise
- Edwards Lifesciences Corp on Thursday reported higher second-quarter earnings on solid sales of its replacement heart valves implanted in a less-invasive procedure than open-heart surgery.
Swiss equity haven may lose out as risk appetite rises
LONDON, July 22 - Signs of an impending retreat from buoyant Swiss stocks may signal the start of a new hunger for risk among investors.
UPDATE 1-Medtronic loses heart valve patent fight in Germany
July 12 - A German court ruled against Medtronic Inc in the latest round of its patent fight with Edwards Lifesciences on Friday, judging the U.S. medical device maker's transcatheter heart valve technology infringes a patent owned by Edwards.
Medtronic loses heart valve patent fight in Germany
July 12 - A German court ruled against Medtronic Inc in the latest round of its patent fight with Edwards Lifesciences on Friday, judging the U.S. medical device maker's heart valve technology infringes a patent owned by Edwards.
Edwards lowers outlook as sales disappoint; shares dive
- Edwards Lifesciences Corp on Tuesday lowered its 2013 outlook due to sluggish sales at the start of the year for its less-invasive replacement heart valves, and its shares plunged 15 percent after hours.
UPDATE 2-Edwards lowers outlook as sales disappoint; shares dive
* Shares plummet 15 percent after hours (Adds earnings details, analyst comments)
BRIEF-Edwards Lifesciences drops 14.6 percent in extended trade
NEW YORK, April 23 - Edwards Lifesciences Corp : * Drops 14.6 percent to $70.75 in extended trade after Q1 results, outlook
Competitors
| Price | Change | |
|---|---|---|
| Medtronic, Inc. (MDT.N) | $55.49 | +0.25 |
| St. Jude Medical, Inc. (STJ.N) | $53.00 | +0.61 |
| Sorin SpA (SORN.MI) | €2.02 | -0.02 |
| ICU Medical, Incorporated (ICUI.OQ) | $73.50 | +1.81 |
| Pulsion Medical Systems SE (PUSG.F) | €12.41 | -0.13 |
| LiDCO Group plc (LID.L) | 15.70p | 0.00 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

